Fluoroquinolone resistance in non-multidrug-resistant tuberculosis-a surveillance study in New South Wales, Australia, and a review of global resistance rates - PubMed (original) (raw)
Fluoroquinolone resistance in non-multidrug-resistant tuberculosis-a surveillance study in New South Wales, Australia, and a review of global resistance rates
Jennifer Ho et al. Int J Infect Dis. 2014 Sep.
Free article
Abstract
Background: Fluoroquinolones (FQs) are used for drug-susceptible tuberculosis (TB) in patients unable to tolerate first-line agents. Current trials are also investigating these drugs in empiric first-line TB therapy, to improve outcomes and allow for shortened treatment regimens. Widespread FQ use in the community has resulted in FQ resistance in many microorganisms, including Mycobacterium tuberculosis. Despite this, FQ drug susceptibility testing (DST) is rarely performed in non-multidrug-resistant TB (non-MDR-TB).
Methods: We conducted a 1-year surveillance study of FQ resistance on all MTB isolates from New South Wales (NSW), Australia. In addition, we performed a literature review of previous studies assessing FQ resistance in non-MDR-TB to summarize the global extent of this resistance pattern.
Results: Two (0.6%) out of 357 MTB isolates from NSW were found to be FQ-resistant. One isolate was an MDR strain (11% of all MDR-TB). The other was isoniazid-monoresistant (0.3% of all non-MDR-TB). Eleven studies from 10 countries had performed FQ resistance surveillance on non-MDR-TB. In the majority of these studies, FQ resistance was found to be low (mean 1%; 95% confidence interval 0.2-2%).
Conclusions: FQ resistance in non-MDR-TB is uncommon in NSW, Australia. The existing global evidence suggests that FQ resistance remains largely confined to MDR-TB strains. In the majority of TB endemic regions, however, FQ resistance in non-MDR-TB has not been assessed. Knowledge of the prevalence of FQ resistance in MTB is essential to guide the rational use of these drugs, including their feasibility as first-line agents.
Keywords: Prevalence; Second-line drug resistance; Susceptibility testing.
Copyright © 2014 The Authors. Published by Elsevier Ltd.. All rights reserved.
Similar articles
- Fluoroquinolone resistance in Mycobacterium tuberculosis isolates from Pakistan 2010-2014: Implications for disease control.
Jabeen K, Shakoor S, Malik F, Hasan R. Jabeen K, et al. Int J Mycobacteriol. 2015 Mar;4 Suppl 1:47-8. doi: 10.1016/j.ijmyco.2014.10.046. Epub 2014 Dec 22. Int J Mycobacteriol. 2015. PMID: 27128617 - Baseline resistance and cross-resistance among fluoroquinolones in multidrug-resistant Mycobacterium tuberculosis isolates at a national reference laboratory in India.
Mamatha HG, Shanthi V. Mamatha HG, et al. J Glob Antimicrob Resist. 2018 Mar;12:5-10. doi: 10.1016/j.jgar.2017.08.014. Epub 2017 Sep 5. J Glob Antimicrob Resist. 2018. PMID: 28887289 - High degree of fluoroquinolone resistance among extrapulmonary tuberculosis patients at a tertiary care center in North India.
Chaubey J, Shrivastava D, Pawar S, Singh BK, Sharma R, Sinha S. Chaubey J, et al. Int J Mycobacteriol. 2020 Jul-Sep;9(3):309-312. doi: 10.4103/ijmy.ijmy_116_20. Int J Mycobacteriol. 2020. PMID: 32862166 - Current prospects for the fluoroquinolones as first-line tuberculosis therapy.
Takiff H, Guerrero E. Takiff H, et al. Antimicrob Agents Chemother. 2011 Dec;55(12):5421-9. doi: 10.1128/AAC.00695-11. Epub 2011 Aug 29. Antimicrob Agents Chemother. 2011. PMID: 21876059 Free PMC article. Review. - The Molecular Genetics of Fluoroquinolone Resistance in Mycobacterium tuberculosis.
Mayer C, Takiff H. Mayer C, et al. Microbiol Spectr. 2014 Aug;2(4):MGM2-0009-2013. doi: 10.1128/microbiolspec.MGM2-0009-2013. Microbiol Spectr. 2014. PMID: 26104201 Review.
Cited by
- Determination of MIC Breakpoints for Second-Line Drugs Associated with Clinical Outcomes in Multidrug-Resistant Tuberculosis Treatment in China.
Zheng X, Zheng R, Hu Y, Werngren J, Forsman LD, Mansjö M, Xu B, Hoffner S. Zheng X, et al. Antimicrob Agents Chemother. 2016 Jul 22;60(8):4786-92. doi: 10.1128/AAC.03008-15. Print 2016 Aug. Antimicrob Agents Chemother. 2016. PMID: 27246779 Free PMC article. - Genomic Analysis of the Evolution of Fluoroquinolone Resistance in Mycobacterium tuberculosis Prior to Tuberculosis Diagnosis.
Zhang D, Gomez JE, Chien JY, Haseley N, Desjardins CA, Earl AM, Hsueh PR, Hung DT. Zhang D, et al. Antimicrob Agents Chemother. 2016 Oct 21;60(11):6600-6608. doi: 10.1128/AAC.00664-16. Print 2016 Nov. Antimicrob Agents Chemother. 2016. PMID: 27572408 Free PMC article. - Second-line Drug Resistance Characterization in Mycobacterium tuberculosis by Genotype MTBDRsl Assay.
Sethi S, Agarwal P, Khaneja R, Kumar N, Kumar N, Chandna J, Aggarwal AN, Yadav R. Sethi S, et al. J Epidemiol Glob Health. 2020 Mar;10(1):42-45. doi: 10.2991/jegh.k.191215.003. J Epidemiol Glob Health. 2020. PMID: 32175709 Free PMC article. - The Relation Between the Emergence of Fluoroquinolone Resistance and Fluoroquinolone Exposure in New Cases of Active Pulmonary Tuberculosis.
Aydın Kayalı R, Özkan SA, Biçmen C, Erer OF. Aydın Kayalı R, et al. Turk Thorac J. 2021 Jan;22(1):45-49. doi: 10.5152/TurkThoracJ.2021.19128. Epub 2021 Jan 1. Turk Thorac J. 2021. PMID: 33646103 Free PMC article. - Genomic Analysis of Mycobacterium tuberculosis Strains Resistant to Second-Line Anti-Tuberculosis Drugs in Lusaka, Zambia.
Chizimu JY, Solo ES, Bwalya P, Kapalamula TF, Mwale KK, Squarre D, Shawa M, Lungu P, Barnes DA, Yamba K, Mufune T, Chambaro H, Kamboyi H, Munyeme M, Hang'ombe BM, Kapata N, Mukonka V, Chilengi R, Thapa J, Nakajima C, Suzuki Y. Chizimu JY, et al. Antibiotics (Basel). 2023 Jun 29;12(7):1126. doi: 10.3390/antibiotics12071126. Antibiotics (Basel). 2023. PMID: 37508222 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical